Development of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
|
|
- Colin McLaughlin
- 5 years ago
- Views:
Transcription
1 Development of a Recombinant Subunit Dengue Vaccine Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
2 Recombinant Subunit Dengue Vaccine Recombinant Envelope Protein Vaccine Hawaii Biotech originally developed subunit vaccine based on carboxy truncated envelope protein 80E Recently acquired by Merck. Drosophila S2 insect cell culture expression system is used to produce dengue subunits No live virus, potential to achieve balanced tetravalent immunity without interference Crystal structure of Merck DEN2-80E protein Steve Harrison, Harvard University 2
3 Recombinant Subunit Dengue Vaccine Overview of Drosophila S2 Expression System Drosophila Expression Vector phbi-20d Gene of Interest Drosophila S2 Cells Native-like Protein Structure Protein Secreted into Culture Medium 3
4 Recombinant Subunit Dengue Vaccine Rationale for Envelope Protein Based Subunit Vaccine Candidate: Functional regions of Envelope are associated with binding to cell receptors and fusion Envelope important in protective immune response key target for neutralizing Ab Envelope also contributes as cell mediated immune target (CD4 and CD8) Balance of multivalent immunity may be manipulated by varying antigen doses no viral interference No prm protein in purified product minimize risk of enhancement linked to anti-prm antibodies 4
5 Dengue Vaccine Formulation Development Formulation Development HBI has tested dengue and WN vaccines with variety of adjuvants in preclinical models. Saponin-based adjuvants and MPL/Alum in combination with DEN antigens induce potent neutralizing responses and protective efficacy in primates Access to potent adjuvants and regulatory challenges led to focus in short term on alum-based adjuvants Alum based formulations immunogenic and efficacious if properly formulated and administered. Focus on alum-based vaccines for initial clinical trial. Other adjuvants may offer significant advantages in long term (durability, dose sparing, magnitude and broadness of immune response) 5
6 Dengue Vaccine Preclinical Studies Non-Human Primate Studies Monovalent DEN-80E studies 1 - Rhesus macaques DEN2-80E + ISCOMATRIX adjuvant 2 - Rhesus macaques DEN2-80E + GSK adjuvants Putnak et al., Rhesus macaques DEN1-80E + alum adjuvant stand alone and prime boost with LAV Tetravalent DEN-80E studies 1 - Rhesus macaques ISCOMATRIX Adjuvant + DEN2 NS1 pilot study 2 - Rhesus macaques ISCOMATRIX adjuvant +/- DEN2 NS1 study large safety, immunogenicity and efficacy study 6
7 Dengue Vaccine Preclinical Studies Monovalent DEN2-80E + GSK adjuvants Rhesus Macaques Immunogenicity and Efficacy 2 doses Challenge 2 months post dose 2 Vaccine Formulation PRNT 50 GMT Viremia (Cell culture) Anamnestic Response 5 μg 80%E + AS04-OH 175 2/3 Yes 20 μg 80%E + AS04-OH 541 0/3 Yes 5 μg 80%E + AS04-PO 114 2/3 Yes 1 μg 80%E + AS /3 Yes 5 μg 80%E + AS /3 Yes 5 μg 80%E + AS /3 Yes 7
8 Dengue Vaccine Preclinical Studies Safety/Immunogenicity/Protection of Tetravalent 80E + NS1 Vaccine in Primates Pilot Study Group Antigen formulation Vaccine Dosing Days Number of Animals 1 3 µg each serotype 80E µg NS1 10 µg Adjuvant A + 10 µg Adjuvant B 2 3 µg each serotype 80E µg NS1 50 µg Adjuvant A + 50 µg Adjuvant B 3 1 µg each serotype 80E µg NS1 60 µg of ISCOMATRIX Adjuvant 4 5 µg each serotype 80E µg NS1 60 µg of ISCOMATRIX Adjuvant 0, 28, 67, , 28, 67, , 28, 67, , 28, 67, Doses - Primary endpoint Safety Safety Profile OK Immunogenicity assessed following each dose Challenge approximately 5 months post dose 4 with DENV2 or DENV4 8
9 PRNT50 Titer PRNT50 Titer Dengue Vaccine Preclinical Studies Anti-DEN-1 Neutralizing Ab Response Neutralizing Ab Responses in Monkeys V3J HJC V2G AC70 AA37 10 FTH T206 AJ14 1 Anti-DEN-2 Neutralizing Ab Response Study Day Study Day V3J HJC V2G AC70 AA37 FTH T206 AJ14 Dark blue: 3 µg each 80E, 0.3 µg NS1, 10 µg each Adjuvant A & Adjuvant B Yellow: 3 µg each 80E, 0.3 µg NS1, 50 µg each Adjuvant A & Adjuvant B Red: 1 µg each 80E, 0.1 µg NS1, 60 µg ISCOMATRIX Adjuvant Blue: 5 µg each 80E, 0.5 µg NS1, 60 µg ISCOMATRIX Adjuvant 9
10 PRNT50 Titer PRNT50 Titer Dengue Vaccine Preclinical Studies Anti-DEN-3 Neutralizing Ab Response Neutralizing Ab Responses in Monkeys V3J HJC V2G AC70 AA37 FTH T206 AJ14 Anti-DEN-4 Neutralizing Ab Response Study Day Study Day V3J HJC V2G AC70 AA37 FTH T206 AJ14 Dark blue: 3 µg each 80E, 0.3 µg NS1, 10 µg each Adjuvant A & Adjuvant B Yellow: 3 µg each 80E, 0.3 µg NS1, 50 µg each Adjuvant A & Adjuvant B Red: 1 µg each 80E, 0.1 µg NS1, 60 µg ISCOMATRIX Adjuvant Blue: 5 µg each 80E, 0.5 µg NS1, 60 µg ISCOMATRIX Adjuvant 10
11 Dengue Vaccine Preclinical Studies PRNT50 Titer Challenge DENV-2 Challenge Anti-DEN-2 Virus Neutralizing Response V3J AC70 FTH AJ14 Protection X Study Day 11
12 Dengue Vaccine Preclinical Studies PRNT50 Titer Challenge DENV-4 Challenge Anti-DEN-4 Virus Neutralizing Response Protection HJC V2G AA37 T206 X X Study Day 12
13 Dengue Vaccine Preclinical Studies Monovalent DEN1-80E + Alhydrogel Rhesus Macaques Recombinant alone or as heterologous primeboost with LAV 3 doses 0, 1, 2 months Challenge 2 months post dose 3 with wild type DEN1 (WP74) Immunogenicity and Efficacy Group Dose 1 Dose 2 Dose 3 1 LAV DEN1-80E DEN1-80E 2 DEN1-80E DEN1-80E LAV 3 DEN1-80E DEN1-80E DEN1-80E 4 Placebo Placebo Placebo 13
14 PRNT 50 GMT Dengue Vaccine Preclinical Studies Monovalent DEN1-80E + Alhydrogel Safety No adverse observations Immunogenicity Virus neutralizing antibody E/LAV LAV/80E 80E/80E Placebo 1 Day 0 Day 28 Day 56 Day 84 Day112 Day140 14
15 Dengue Vaccine Preclinical Studies Monovalent DEN1-80E + Alhydrogel Efficacy - Post Challenge Viremia Results Group Viremia # Animals (mean # days) 1 - LAV/DEN1/DEN1 0/3 2 - DEN1/DEN1/LAV 0/3 3 - DEN1/DEN1/DEN1 0/3 4 - Alhydrogel Placebo 3/3 (4.33) 15
16 Dengue Vaccine Preclinical Studies Tetravalent DEN-80E + ISCOMATRIX Adjuvant Rhesus Macaques +/- DEN2-NS1 3 0, 2, 4 months 3 groups of 12 monkeys each challenge 5 months post dose 3 3 monkeys challenged with each serotype Immunogenicity and Efficacy Formulation DEN 80%E DEN-2 NS1 ISCOMATRIX A 1 µg each 80%E - 60 µg B 1 µg each 80%E 0.1 µg 60 µg Placebo µg 16
17 Dengue Vaccine Preclinical Studies Tetravalent DEN-80E + ISCOMATRIX Adjuvant Safety - no adverse local reactions or impact on clinical chemistry/hematology parameters Post dose 3 PRNT 50 titers - Representative results Virus Serotype PRNT DEN-1 DEN-2 DEN-3 DEN-4 GMTs
18 Dengue Vaccine Preclinical Studies Tetravalent DEN-80E + ISCOMATRIX Adjuvant Efficacy - Post Challenge Viremia Data Group Challenge Virus Viremia # Animals (mean # days) 1 μg each DEN1 0/3 (0) Tetravalent 80E DEN2* 0/3 (0) + ISCOMATRIX Adjuvant DEN3 0/3 (0) DEN4* 0/3 (0) 1 μg each DEN1 1/3 (0.33) Tetravalent 80E DEN2* 0/3 (0) μg NS1 DEN3 0/3 (0) + ISCOMATRIX Adjuvant DEN4* 0/3 (0) DEN1 3/3 (5) ISCOMATRIX DEN2* 3/3 (2.3) Adjuvant Control DEN3 3/3 (3.7) DEN4* 2/3 (1.7) * Amplification on C6/36 prior to plaquing on Vero 18
19 Dengue Vaccine Preclinical Safety Studies Preclinical Toxicity Testing GLP Rat repeat dose safety study to assess local and systemic toxicity of vaccine antigens alone or formulated with ISCOMATRIX Adjuvant No significant toxicity/reactogenicity found with vaccine antigens or formulated vaccine GLP Rabbit repeat dose safety study to assess local and systemic toxicity of antigens alone or in alum based formulation No toxicity/reactogenicity with any formulation Group Formulation 1 Vehicle Control - PBS 2 Alhydrogel 85 Adjuvant Control 3 Antigen Control Tetravalent 80E + DEN2 NS1 4 DEN1-80E adsorbed on Alhydrogel 85 5 Tetravalent 80E + DEN2 NS1 adsorbed on Alhydrogel 85 19
20 Dengue Vaccine Preclinical Safety Studies Preclinical Toxicity Testing GLP Rabbit repeat dose safety study to assess local and systemic toxicity of antigens alone or in alum based formulation Immunogenicity results post dose 3 Group Formulation DEN1 ELISA EC 50 GMT 1 Vehicle Control PBS <250 2 Alhydrogel 85 Adjuvant Control <250 3 Antigen Control Tetravalent 80E + DEN2 NS DEN1-80E adsorbed on Alhydrogel * 5 Tetravalent 80E + DEN2 NS1 adsorbed on Alhydrogel * PRNT GMT
21 Recombinant Subunit Clinical Study Phase 1 Monovalent Clinical Study COHORT 1 N=8 2 N=8 TREATMENT Low dose DEN1-80E 10 µg + Alhydrogel 1.25 mg Al High dose DEN1-80E 50 µg + Alhydrogel 1.25 mg Al Placebo-controlled, double-blind study 6 active, 2 placebo per cohort Dose escalation low and high doses 3 doses administered at 0, 1, 2 months Primary endpoint safety Immunogenicity evaluation virus neutralizing antibody Last subject, last visit in June Study still blinded. 21
22 Recombinant Subunit Clinical Study GMT PRNT50 Titers Virus Neutralizing Antibody Preliminary Results Dose 1 Dose 2 Dose Cohort 1 10µg +Alum Cohort 2 50µg +Alum 10 Placebo 1 Week 0 Week 2 Week 4 Week 6 Week 8 Week 10 22
23 Recombinant Subunit Clinical Study Conclusions: Based on preliminary, unaudited, blinded data - monovalent DEN1-80E vaccine adjuvanted with aluminum hydroxide is immunogenic in healthy, adult, flavivirus-naïve volunteers consistent with preclinical data. Study included a dose escalation with monitoring by a Safety Committee - no safety signals Demonstrates potential of the recombinant proteins. Plans for testing of tetravalent product under development 23
24 Acknowledgements Saint Louis University Center for Vaccine Development Sarah George Nicole Purcell Carolyn Stefanski Linda Eggemeyer All the Study Volunteers Johns Hopkins University Anna Durbin Janece Lovchik Walter Reed Army Institute for Research Ken Eckels Rick Millward Stephen Thomas David Bradley Amy Dean Robert Putnak University of Texas Medical Branch Robert Tesh CSL Clinical and Statistical Support Debbie Drane Martin Pearse Elenie Bartzokis Steve Honey Gary Stevens Hawaii Biotech, Inc. Jon Ruckle Maile O Connell Tim Martyak Mike Thorne Vidya Pai Robbin Henley David Clements Michele Yelmene Support from: U.S. Department of Defense, National Institutes of Allergy and Infectious Disease, Pediatric Dengue Vaccine Initiative, State of Hawaii, Merck, and Hawaii Biotech Investors 24
Making Dengue a Vaccine Preventable Disease
Making Dengue a Vaccine Preventable Disease Harold S. Margolis, MD, FAAP Joint International Tropical Medicine Meeting (JITMM) Bangkok, Thailand October 13, 2008 Dengue Vaccines Where are We Today? No
More informationDengue and Zika vaccine development
Dengue and Zika vaccine development Carolyn E. Clark, PhD, MPH Scientist, Infection Control and Environmental Health Norwegian Institute of Public Health Kurs i import- og reisemedisin for helsepersonell
More informationUpdate on the NIH tetravalent dengue vaccine. Beulah Sabundayo, PharmD, MPH Johns Hopkins Bloomberg School of Public Health
Update on the NIH tetravalent dengue vaccine Beulah Sabundayo, PharmD, MPH Johns Hopkins Bloomberg School of Public Health 1 Tetravalent studies in DENV naïve adults Potency (log Vaccine Components: 10
More informationDengue Vaccine Butantan Institute. DCVMN, Bangkok, 2015
Dengue Vaccine Butantan Institute DCVMN, Bangkok, 2015 GENOME Dengue Viruses Dengue is a mosquito-borne RNA virus with 4 distinct serotypes: 1,2,3,and 4 3 structural proteins: C, prm, and E E protein is
More informationFlavivirus Vaccines Japanese Encephalitis and Dengue
Flavivirus Vaccines Japanese Encephalitis and Dengue 14 th Advanced Vaccinology Course Veyrier du Lac, France May 16, 2012 Harold S. Margolis, MD Dengue Branch Centers for Disease Control and Prevention
More informationPre-clinical Development of a Dengue Vaccine. Jeremy Brett Sanofi Pasteur, Singapore
Pre-clinical Development of a Dengue Vaccine Jeremy Brett Sanofi Pasteur, Singapore Dengue Vaccine B Guy 1 Talk flow Introduction: What are the challenges of dengue vaccine development? The Virus The host
More informationDengue: The next vaccine preventable disease? Prof John McBride James Cook University
Dengue: The next vaccine preventable disease? Prof John McBride James Cook University Dengue viruses A flavivirus ~11kb genome, ~50nm diameter, lipid envelope. Gene order 5 C-prM-E-NS1 Four serotypes (1-4)
More informationCanadian Immunization Conference 2018 Dec 4
Enveloped Virus-Like Particle (evlp) Cytomegalovirus (CMV) Vaccine is immunogenic and safe: preliminary results of a First-in-Humans Canadian Immunization Network (CIRN) Clinical Trials Network (CTN) -
More informationDeveloping a dengue vaccine: progress and future challenges
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: Antimicrobial Therapeutics Reviews Developing a dengue vaccine: progress and future challenges Stephen J. Thomas Walter
More informationImmune protection against dengue infection. Vaccine performance
Immune protection against dengue infection. Vaccine performance SCOTT B HALSTEAD MD Department of Preventive Medicine Uniformed Services University of the Health Sciences TOPICS Current dengue vaccines:
More informationWhat is the role of animal models in studying protective titres and the need for establishing surrogates/correlates of protection?
What is the role of animal models in studying protective titres and the need for establishing surrogates/correlates of protection? Alan D.T. Barrett Department of Pathology and Sealy Center for Vaccine
More informationSafety and Immunogenicity of a Parenterally Administered Rotavirus VP8 Subunit Vaccine in Healthy Adults
Safety and Immunogenicity of a Parenterally Administered Rotavirus VP8 Subunit Vaccine in Healthy Adults Stanley Cryz 1, Clayton Harro 2, Monica McNeal 3, Nicole Meyer 3, Barbara DeNearing 2, Alicia Cage
More informationCorrelates of Protection in Dengue. Stephen J. Thomas, MD Division of Infectious Diseases State University of New York Upstate Medical University
Correlates of Protection in Dengue Stephen J. Thomas, MD Division of Infectious Diseases State University of New York Upstate Medical University May 2017 Discussion of correlates requires clarity and proper
More informationA Recombinant Tetravalent Dengue Vaccine Candidate Using DENV-2 Backbone
A Recombinant Tetravalent Dengue Vaccine Candidate Using DENV-2 Backbone First Regional Dengue Symposium, Rio de Janeiro, Brazil Nov 3-4 2015 Pedro Garbes, MD. Regional Medical Director, Latin America.
More informationNew prospects for vaccination: from polio to dengue and flu
New prospects for vaccination: from polio to dengue and flu From ancient Chinese variolation to Jenner and cowpox Paul Young Australian Infectious Diseases Research Centre School of Chemistry and Molecular
More informationDevelopment of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com
More informationLong-term Immunogenicity Following Vaccination with a New, Live-attenuated Vaccine Against Japanese Encephalitis (JE-CV)
Long-term Immunogenicity Following Vaccination with a New, Live-attenuated Vaccine Against Japanese Encephalitis (JE-CV) Sutee Yoksan, M.D., Ph.D. Center for Vaccine Development, Mahidol University Joint
More informationJoseph E. Blaney, Jr.,* Jennifer M. Matro, Brian R. Murphy, and Stephen S. Whitehead
JOURNAL OF VIROLOGY, May 2005, p. 5516 5528 Vol. 79, No. 9 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.9.5516 5528.2005 Recombinant, Live-Attenuated Tetravalent Dengue Virus Vaccine Formulations Induce a
More informationsp second generation tetravalent dengue vaccine
sp second generation tetravalent dengue vaccine CYD23 Study Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 1 Years in Thailand Alain Bouckenooghe, MD, MPH, DTM&H Clinical R&D, Head
More informationPERSPECTIVES IN THE DEVELOPMENT OF VACCINES AGAINST FLAVIVIRUSES. M. Rossman. Thomas P Monath MD
PERSPECTIVES IN THE DEVELOPMENT OF VACCINES AGAINST FLAVIVIRUSES M. Rossman Thomas P Monath MD Agenda State of the art of flavivirus vaccines Second generation vaccines Rational design, balancing attenuation
More informationMathematical Models for the Control of Infectious Diseases With Vaccines
Mathematical Models for the Control of Infectious Diseases With Vaccines Ira Longini Department of Biostatistics and Center for Statistical and Quantitative Infectious Diseases (CSQUID), University of
More informationDengue Vaccines: current status of development
Dengue Vaccines: current status of development ISID-NTD 2011 International Meeting, Boston Satellite Symposium on Dengue Control, 10 July 2011 Pem Namgyal WHO/IVB/IVR 1 Presentation Outline! Summary of
More informationMeeting of the WHO Task Force on Clinical Trials of Dengue Vaccines
VWHO/IVB/07.11 ORIGINAL: ENGLISH Meeting of the WHO Task Force on Clinical Trials of Dengue Vaccines Atlanta, GA, USA 11 November 2006 Immunization, Vaccines and Biologicals I V BMeeting WHO/IVB/07.11
More informationShould There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy
More informationDengue Vaccines: Status and Future
Dengue Vaccines: Status and Future In-Kyu Yoon, M.D. International Vaccine Institute Director, Global Dengue & Aedes-Transmitted Diseases Consortium 22 Jun 2018 Outline Tetravalent vaccination strategy
More informationDevelopment of live attenuated pediatric RSV vaccines
Development of live attenuated pediatric RSV vaccines Laboratory of Infectious Diseases, NIAID, NIH (Ursula Buchholz, Peter Collins) Center for Immunization Research, JHU (Ruth Karron) Infant with RSV
More informationCOUNTERING EMERGING INFECTIOUS DISEASE THREATS
COUNTERING EMERGING INFECTIOUS DISEASE THREATS AN ARMY ACCELERATED RESPONSE TO ZIKA KAYVON MODJARRAD, MD, PHD DIRECTOR, EMERGING INFECTIOUS DISEASE THREATS The views expressed in this presentation are
More informationRecent advances in human flavivirus vaccines
Recent advances in human flavivirus vaccines Iris Scherwitzl 1, Juthathip Mongkolsapaya 1,2, Gavin Screaton 1 Addresses 1 Department of Medicine, Imperial College London, W12 0NN London, UK 2 Faculty of
More informationTarget Design and Immunogenicity
Target Design and Immunogenicity 03-18-2013 Vidadi Yusibov New Cells, New Vaccines VII: From Protein to Product Vaccine Products Conventional vaccines: Inactivated Live, attenuated Toxoid Recombinant Subunit
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More informationHIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationMODULE 5. Dengue. Edwin J. Asturias Associate Professor of Pediatrics Senior Investigator Director for Latin America
MODULE 5 Dengue Edwin J. Asturias Associate Professor of Pediatrics Senior Investigator Director for Latin America Symptoms of Dengue Fever Dengue: Skin rashes DHF manifestations Hemorrhages Thrombocytopenia
More informationReceived 8 February 2006/Accepted 10 July 2006
JOURNAL OF VIROLOGY, Oct. 2006, p. 9577 9585 Vol. 80, No. 19 0022-538X/06/$08.00 0 doi:10.1128/jvi.00284-06 Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and
More informationCurrent Dengue Vaccine Status
Curr Trop Med Rep (2014) 1:6 12 DOI 10.1007/s40475-013-0006-3 VIRAL TROPICAL MEDICINE (CM BEAUMIER) Current Dengue Vaccine Status Leyi Lin & Stephen J. Thomas Published online: 21 December 2013 # Springer
More informationAntibody Recognition of the Dengue Virus Proteome and Implications for Development of Vaccines
CLINICAL AND VACCINE IMMUNOLOGY, Apr. 2011, p. 523 532 Vol. 18, No. 4 1556-6811/11/$12.00 doi:10.1128/cvi.00016-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Antibody Recognition
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationZika: Deet, There It Is. Anna Powell, MD Reproductive Infectious Disease Fellow THEGOS
Zika: Deet, There It Is Anna Powell, MD Reproductive Infectious Disease Fellow THEGOS Disclosure I have no financial disclosures or conflicts of interest Lessons from Rubella At peak of rubella epidemic
More informationNON HUMAN PRIMATE BIOMEDICAL RESEARCH FOR TACKLING EMERGING INFECTIOUS DISEASES (II): ZIKA VIRUS. Special series on Laboratory Animal Science
NON HUMAN PRIMATE BIOMEDICAL RESEARCH FOR TACKLING EMERGING INFECTIOUS DISEASES (II): ZIKA VIRUS Special series on Laboratory Animal Science SPECIAL SERIES ON LABORATORY ANIMAL SCIENCE Signature by Adriano
More informationSecondary Zika virus infection do not support evidences of Antibody-Dependent Enhancement in vivo in dengue pre-exposed rhesus macaques
University of Puerto Rico Medical Sciences Campus Caribbean Primate Research Center Secondary Zika virus infection do not support evidences of Antibody-Dependent Enhancement in vivo in dengue pre-exposed
More informationDevelopment of dengue vaccines
Development of dengue vaccines Chee Siean Lim, Chit Laa Poh Centre for Virus and Vaccine Research, Sunway University, Selangor, Malaysia REVIEW Please cite this paper as: Lim CS, Poh CL. Development of
More informationProtection of Rhesus Monkeys against Dengue Virus Challenge after Tetravalent Live Attenuated Dengue Virus Vaccination
MAJOR ARTICLE Protection of Rhesus Monkeys against Dengue Virus Challenge after Tetravalent Live Attenuated Dengue Virus Vaccination Wellington Sun, 1 Ananda Nisalak, 3 Montip Gettayacamin, 4 Kenneth H.
More informationEPIDEMIOLOGICAL STUDIES
EPIDEMIOLOGICAL STUDIES EPIDEMIOLOGIC STUDIES EPIDEMIOLOGIC STUDIES 8 Clinical Trial sites in Brasil (NICHD) Transfusion recipient study (NHLBI) Prospective study in Brasil (Yale) Natural history population
More informationLecture 9: Stochastic models for arboviruses. Ira Longini
Lecture 9: Stochastic models for arboviruses Ira Longini The Ross-MacDonald Model for Vector Bourne Infectious Diseases Sir Ronald Ross (1857-1932) Liverpool School of Tropical Medicine The 2 nd Nobel
More informationPreclinical and Clinical Development of a YFV 17 D-Based Chimeric Vaccine against West Nile Virus
Viruses 2013, 5, 3048-3070; doi:10.3390/v5123048 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Preclinical and Clinical Development of a YFV 17 D-Based Chimeric Vaccine against
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION NOVEMBER 2018 1 Cautionary Statement Regarding Forward-Looking Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are
More informationResults of Phase III Efficacy Studies in Dengue Endemic Regions of the Sanofi Pasteur Candidate Dengue Vaccine
Results of Phase III Efficacy Studies in Dengue Endemic Regions of the Sanofi Pasteur Candidate Dengue Vaccine Maria Rosario Z. Capeding, MD Research Institute for Tropical Medicine Philippines From
More informationSEROLOGICAL DIAGNOSIS OF DENGUE INFECTIONS
ECDC training Workshop on laboratory diagnosis of dengue virus infections Berlin, 23 27 January 2012 SEROLOGICAL DIAGNOSIS OF DENGUE INFECTIONS Cristina Domingo Carrasco Robert Koch Institut FACILITIES
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationH5N1 and H7 LAIV-IAV Prime-Boost Studies
NIAID H5N1 and H7 LAIV-IAV Prime-Boost Studies Kanta Subbarao, MD, MPH NIAID, NIH The LID Pandemic Influenza Vaccine Program Program: CRADA with MedImmune Clinical Trials: Center for Immunization Research,
More information2008 LANDES BIOSCIENCE. DO NOT DISTRIBUTE.
[Human Vaccines 5:1, 33-40; January 2009]; 2009 Landes Bioscience Research Paper Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults Wellington
More informationPart B. Nonclinical evaluation of dengue tetravalent vaccines (live, attenuated) 81
Annex 2 Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated) Replacement of Annex 1 of WHO Technical Report Series, No. 932 Abbreviations 55 Introduction 55
More informationDengue-2 Vaccine: Viremia and Immune Responses in Rhesus Monkeys
INFECTION AND IMMUNITY, Jan. 1980, p. 181-186 0019-9567/80/01-0181/06$02.00/0 Vol. 27, No. 1 Dengue-2 Vaccine: Viremia and Immune Responses in Rhesus Monkeys ROBERT McN. SCOTT,'t* ANANDA NISALAK,' KENNETH
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCLINICAL RELEVANCE. D. A. Grosenbaugh, DVM, PhD a C. S. Backus, DVM, PhD b K. Karaca, DVM, PhD a J. M. Minke, DVM, PhD c R. M. Nordgren, DVM, PhD a
The Anamnestic Serologic Response to Vaccination with a Canarypox Virus Vectored Recombinant West Nile Virus (WNV) Vaccine in Horses Previously Vaccinated with an Inactivated WNV Vaccine* D. A. Grosenbaugh,
More informationUpdate on influenza vaccination using microneedle delivery
Mark Prausnitz serves as a consultant and is an inventor on patents licensed to companies developing products related to this presentation. This potential conflict of interest is being managed by Georgia
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationClinical overview of GSK s AS04 adjuvanted vaccine: data up to 6.4 years
Clinical overview of GSK s AS04 adjuvanted vaccine: data up to 6.4 years Gudrun Maechler Director, Clinical & Medical Affairs Europe & Cervarix GSK Biologicals Presentation Outline HPV immunology Immunogenicity
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen. Results of the Thai HIV Vaccine Trial, RV144
ALVAC -HIV and AIDSVAX B/E Prime-Boost HIV-1 Preventive Vaccine Regimen Results of the Thai HIV Vaccine Trial, RV144 SupachaiRerks-Ngarm, PunneePittisutthithum, SorachaiNitayaphan, JaranitKaewkungwal,
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More information111 II1 I 111 III ? 0 9, AD-A CT 31i931 ANNUAL REPORT D TIC RDMUNDO KRAISELBURD S AUGUST 28, 1991.
AD-A242 097 III 111 II1 I 111 AD COMPARATIVE INFECTIVITY DETERMINATION OF DENGUE VIRUS VACCINE CANDIDATES IN RHESUS MONKEYS, MOSQUITOES, AND CELL CULTURE ANNUAL REPORT D TIC CT 31i931 RDMUNDO KRAISELBURD
More informationGuidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated)
ENGLISH ONLY FINAL Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated) Proposed replacement of Annex 1 of WHO Technical Report Series, No. 932 World Health
More informationDevelopment of Recombinant Pertussis Vaccines
Development of Recombinant Pertussis Vaccines Wassana Wijagkanalan, PhD BioNet-Asia Co., Ltd, Bangkok, Thailand DCVMN Workshop: Global Registration and Vaccine Shortage 6-10 March 2017, Taipei, Taiwan
More informationThe Pediatric Dengue Vaccine Initiative (PDVI) Thailand, 2007
The Pediatric Dengue Vaccine Initiative (PDVI) Thailand, 2007 The Vaccine Enterprise-the the disease Clinical data Surveillance data Laboratory data/diagnostics Input, analysis and reporting The Vaccine
More informationYellow fever vaccination in HIV patients
INFECTIOUS DISEASES DEPARTMENT AIDS REFERENCE CENTRE Yellow fever vaccination in HIV patients Dr Ch. MARTIN Travel & Vaccine Clinic CHU Saint-Pierre, Brussels Respect Innovation Engagement Solidarity Quality
More informationDengue Experience and Implications for Vaccine Development
Dengue Experience and Implications for Vaccine Development In-Kyu Yoon, M.D. International Vaccine Institute Director, Global Dengue & Aedes-Transmitted Diseases Consortium 28 Jun 2018 Mission: To promote
More informationGSK s RSV vaccine product development overview
GSK s RSV vaccine product development overview Introduction GSK maternal and paediatricrsv programs are in early stage of development (Phase I/II) For both programs, GSK is targeting a global development
More informationCORPORATE OVERVIEW NASDAQ: VBIV JUNE 2018 NASDAQ: VBIV
CORPORATE OVERVIEW JUNE 2018 1 Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationFlaviviruses New Challenges, New Vaccines
Flaviviruses New Challenges, New Vaccines Christian W. Mandl Institute of Virology Medical University of Vienna, AUSTRIA Family Flaviviridae Genus Hepacivirus Genus Pestivirus Genus Flavivirus (>70 members)
More informationZika Virus Infection in Cynomolgus Macaques
Zika Virus Infection in Cynomolgus Macaques Fusataka Koide Program Leader, Emerging Pathogens Background Mosquito-borne virus belonging to the flavivirus genus of the Flaviviridae family. Dengue viruses,
More informationNew Technology in Vaccine Engineering
Viruses in May Katoomba, August, 2012 New Technology in Vaccine Engineering Anton Middelberg Australian Institute for Bioengineering and Nanotechnology The University of Queensland, Australia Introduction
More informationDengue Human Infection Model Performance Parameters
SUPPLEMENT ARTICLE Dengue Human Infection Model Performance Parameters Timothy P. Endy Infectious Disease Division, Department of Medicine, State University of New York, Upstate Medical University, Syracuse
More informationWHO Working Group on Technical Specifications for Manufacture and Evaluation of Dengue Vaccines
Distribution: General English only Meeting Report WHO Working Group on Technical Specifications for Manufacture and Evaluation of Dengue Vaccines Geneva, Switzerland 11-12 May 2009 1 1 Disclaimer: This
More informationCORPORATE OVERVIEW NASDAQ: VBIV TSX: VBV NOVEMBER 2017 NASDAQ: VBIV TSX: VBV
CORPORATE OVERVIEW NASDAQ: VBIV TSX: VBV NOVEMBER 2017 1 Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation that are forward-looking and not statements of
More informationLynn Morris. "Plan B"- bnabs for HIV prevention
"Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,
More informationTransforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago
Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2
More informationDOI: /ICJ (Dengue fever) [2] (Aedes aegypti) (Aedes albopictus) (Dengue. (Flavivirus) 50 nm. ssrna) (capsid, C) ( ) (membrane, prm/m)
210 DOI: 10.6526/ICJ.2016.504 T (Dengue fever) [1] 128 39 [2] 4 5 21,000 [3] 3 1981 1987 1995 2014 [4] 2015 ( ) (Aedes aegypti) (Aedes albopictus) (Dengue virus) (Flaviviridae) (Flavivirus) 50 nm 11 kb
More informationRegulatory Considerations for Determining Vaccine Efficacy U.S. FDA Perspective
Regulatory Considerations for Determining Vaccine Efficacy U.S. FDA Perspective Marion Gruber, PhD. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research Food and Drug
More informationLaboratory Testing for West Nile Virus Infections Testing Human & Non-Human Tissues
Laboratory Testing for West Nile Virus Infections Testing Human & Non-Human Tissues Robert S Lanciotti Chief; Diagnostic & Reference Laboratory Arbovirus Diseases Branch Fort Collins, Colorado Presentation
More informationTherapeutic vaccines for HCV Chasing a Moving Target
Therapeutic vaccines for HCV Chasing a Moving Target Ellie Barnes (Fondation Merieux-Annecy March 213) Do we need a vaccine for HCV? HCV infects 17 million people worldwide Leading cause of end-stage
More informationCORPORATE OVERVIEW NASDAQ: VBIV TSX: VBV
CORPORATE OVERVIEW NASDAQ: VBIV M A R C H 2 0 1 81 Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation that are forward-looking and not statements of historical
More informationHuman metapneumovirus (hmpv) and parainfluenza virus 3 (PIV3) vaccine (mrna-1653)
Human metapneumovirus (hmpv) and parainfluenza virus 3 (PIV3) vaccine (mrna-1653) Conference Call February 12, 2019 Flu H10N8 H7N9 Prophylactic vaccines RSV VZV CMV hmpv+piv3 Chikungunya VLP Zika VLP Cancer
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationEnhancing the Immunogenicity of a Tetravalent Dengue DNA Vaccine
AWARD NUMBER: W81XWH-15-2-0029 TITLE: Enhancing the Immunogenicity of a Tetravalent Dengue DNA Vaccine PRINCIPAL INVESTIGATOR: Maya Williams CONTRACTING ORGANIZATION: Henry M. Jackson Foundation For the
More informationFoot and Mouth Disease Vaccine Research and Development in India
Foot and Mouth Disease Vaccine Research and Development in India R.Venkataramanan Indian Veterinary Research Institute, Hebbal, Bangalore 560 024 Foot and Mouth Disease in India Present Status Large Susceptible
More informationDengue Vaccines: Herd Immunity Considerations
1/33 Dengue Vaccines: Herd Immunity Considerations Derek Cummings Johns Hopkins Bloomberg School of Public Health Fondation Merieux, October 27, 2010 2/33 Outline 1 2 3 Immune enhancement of transmission
More informationRole of a ZIKV CHIM in vaccine evaluation. Anna Durbin Johns Hopkins Bloomberg School of Public Health WHO Zika Workshop, Geneva 2 June 2017
Role of a ZIKV CHIM in vaccine evaluation Anna Durbin Johns Hopkins Bloomberg School of Public Health WHO Zika Workshop, Geneva 2 June 2017 1 ZIKV congenital syndrome There is increasing evidence from
More informationStatus of Vaccine Research and Development for Norovirus Prepared for WHO PD-VAC
Status of Vaccine Research and Development for Norovirus Prepared for WHO PD-VAC I. About the Disease and Pathogen Basic information on pathogen, including transmission, estimated global disease burden
More informationDevelopment of a Novel Recombinant Influenza Vaccine in Insect Cells
Development of a Novel Recombinant Influenza Vaccine in Insect Cells Clifton McPherson New Cells for New Vaccines II September 18, 2007 cmcpherson@proteinsciences.com New Cell for New Vaccines II Topics:
More informationMaría G. Guzmán Instituto Medicina Tropical Habana, Junio Dengue Vaccine Development Cuban studies
María G. Guzmán Instituto Medicina Tropical Habana, Junio 2004 Dengue Vaccine Development Cuban studies Four viruses Dengue Virus Ab ADE Hyphotesis Fc RECEPTOR CELL {Four Four viruses {ADE {No Animal Model
More informationDengue vaccines: what we know, what has been done, but what does the future hold?
Rev Saúde Pública 2015;49:60 Comentário DOI:10.1590/S0034-8910.2015049006146 Emiliana Pereira Abrão Danillo Lucas Alves Espósito Flávio Lauretti Benedito Antonio Lopes da Fonseca Dengue vaccines: what
More informationValneva s Lyme vaccine candidate VLA15
Valneva s Lyme vaccine candidate VLA15 New York December 12, 2016 Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva
More informationEvidence review on the immunogenicity, efficacy/effectiveness and safety of typhoid conjugate vaccines
Evidence review on the immunogenicity, efficacy/effectiveness and safety of typhoid conjugate vaccines SAGE meeting, Geneva, 17-19 October, 2017 Myron M. (Mike) Levine, MD, DTPH Grollman Distinguished
More informationNASDAQ:NVAX Novavax, Inc. All rights reserved.
Novavax vaccine induced improved immune responses against homologous and drifted A(H3N2) viruses in older adults compared to egg-based, high-dose, influenza vaccine World Vaccine Congress April 4, 2018
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Center: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Ehrlich HJ, Müller M, Oh HML, et al. A clinical trial of a
More informationSPECIFIC ANTIINFECTIOUS IMMUNITY. colostral immunity. administration of antibodies VIRULENT VACCINE INACTIVATED VACCINE
INDUCTION OF IMMUNITY AGAINST INFECTION SPECIFIC ANTIINFECTIOUS IMMUNITY active passive S AND VACCINATION infection vaccination colostral immunity administration of antibodies VIRULENT MODIFIED LIVE INACTIVATED
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More information